Cost-effectiveness of a Community-based Hypertension Improvement Project (ComHIP) in Ghana: results from a modelling study. by Pozo-Martin, Francisco et al.
1Pozo- Martin F, et al. BMJ Open 2021;11:e039594. doi:10.1136/bmjopen-2020-039594
Open access 
Cost- effectiveness of a Community- 
based Hypertension Improvement 
Project (ComHIP) in Ghana: results 
from a modelling study
Francisco Pozo- Martin   ,1,2 James Akazili,3,4 Reina Der,5,6 Amos Laar,7 
Alma J Adler   ,8 Peter Lamptey,6,9 Ulla K Griffiths,2,10 Anna Vassall2
To cite: Pozo- Martin F, 
Akazili J, Der R, et al.  
Cost- effectiveness of a 
Community- based Hypertension 
Improvement Project (ComHIP) 
in Ghana: results from a 
modelling study. BMJ Open 
2021;11:e039594. doi:10.1136/
bmjopen-2020-039594
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online. 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2020- 039594).
Received 08 June 2020
Accepted 27 July 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Francisco Pozo- Martin;  
 fpozomartin@ gmail. com
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objective To undertake a cost- effectiveness analysis of 
a Community- based Hypertension Improvement Project 
(ComHIP) compared with standard hypertension care in 
Ghana.
Design Cost- effectiveness analysis using a Markov 
model.
Setting Lower Manya Krobo, Eastern Region, Ghana.
Intervention We evaluated ComHIP, an intervention 
with multiple components, including: community- based 
education on cardiovascular disease (CVD) risk factors 
and healthy lifestyles; community- based screening and 
monitoring of blood pressure by licensed chemical sellers 
and CVD nurses; community- based diagnosis, treatment, 
counselling, follow- up and referral of hypertension 
patients by CVD nurses; telemedicine consultation by CVD 
nurses and referral of patients with severe hypertension 
and/or organ damage to a physician; information and 
communication technologies messages for healthy 
lifestyles, treatment adherence support and treatment refill 
reminders for hypertension patients; Commcare, a cloud- 
based health records system linked to short- message 
service (SMS)/voice messaging for treatment adherence, 
reminders and health messaging. ComHIP was evaluated 
under two scale- up scenarios: (1) ComHIP as currently 
implemented with support from international partners and 
(2) ComHIP under full local implementation.
Main outcome measures Incremental cost per 
disability- adjusted life- year (DALY) averted from a societal 
perspective over a time horizon of 10 years.
Results ComHIP is unlikely to be a cost- effective 
intervention, with current ComHIP implementation and 
ComHIP under full local implementation costing on average 
US$12 189 and US$6530 per DALY averted, respectively. 
Results were robust to uncertainty analyses around model 
parameters.
Conclusions High overhead costs and high patient costs 
in ComHIP suggest that the societal costs of ensuring 
appropriate hypertension care are high and may not 
produce sufficient impact to achieve cost- effective 
implementation. However, these results are limited by 
the evidence quality of the effectiveness estimates, 
which comes from observational data rather than from 
randomised controlled study design.
INTRODUCTION
High blood pressure is the leading cause of 
cardiovascular disease (CVD) and deaths 
worldwide.1 The prevalence of hypertension 
in low- income and middle- income countries 
(LMICs), where over 80% of CVD mortality 
occurs worldwide,2 is estimated to be as high 
or higher than in many high- income coun-
tries.3 In a systematic review of the burden 
of hypertension in sub- Saharan Africa (SSA), 
the overall prevalence of hypertension was 
estimated at 30%.4 For individuals with hyper-
tension, treatment with antihypertensive 
drugs substantially reduces the risk of CVD 
events, such as stroke, myocardial infarction 
and heart failure.5 In Ghana, hypertension 
is an important public health problem, with 
its prevalence in adults being estimated to 
be between 19% and 48%.6 CVD is also an 
important public health problem, having 
been identified as the second leading cause 
of death after diarrhoeal diseases.7 8 A cross- 
sectional analysis using data from the 2014 
Ghana Demographic and Health Survey 
Strengths and limitations of this study
 ► Previous studies have not considered the cost- 
effectiveness of comprehensive hypertension con-
trol strategies incorporating community- based 
screening and management of hypertension pa-
tients as well as information technology tools to 
support patient education and treatment adherence.
 ► This economic evaluation used patient- level data 
from a large before- and- after study of such a 
community- based model of hypertension care.
 ► A comprehensive and detailed costing study of the 
community- based hypertension care model was un-
dertaken from a societal perspective.
 ► The before- and- after study from which the esti-
mates of effectiveness are derived did not include 
a control group.
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(DHS) showed that 45.6% of hypertensive individuals 
were aware of their condition, 40.5% were on hyperten-
sion treatment, and only 23.8% had their blood pressure 
controlled.9
Previous estimates of the costs and cost- effectiveness 
of hypertension treatment have suggested that it has the 
potential to be cost- effective in SSA.10–13 Based on model-
ling studies undertaken for the whole of SSA, Murray et al11 
Ortegón et al12 and Mendis et al13 found that hypertension 
treatment and education interventions in high- risk indi-
viduals were cost- effective. Rosendaal et al10 estimated, in 
the context of rural Nigeria, that a hypertension screening, 
treatment and lifestyle advice intervention could be cost- 
effective.10 However, in a context of low hypertension 
control,4 9 these previous studies did not include the costs 
of increasing coverage and adherence by enabling inter-
ventions which, in addition to providing hypertension 
treatment, use both information and communication 
technologies (ICTs) and community- based screening and 
management for the control of hypertension. We present 
here a cost- effectiveness analysis of such a comprehensive 
intervention to scale up hypertension treatment services 
at the community level; the Community- based Hyperten-
sion Improvement Project (ComHIP) in Ghana.
METHODS
Study setting and intervention
ComHIP was a 2- year hypertension control programme 
led by the Ghana Health Service (GHS) with support 
from the international non- profit organisation FHI360. 
ComHIP is based on a public–private partnership. The 
private sector is engaged through licensed chemical sellers 
(LCS), who are community pharmacists. The project uses 
ICTs and task shifting to enhance the capacity of the 
GHS to improve management and control of hyperten-
sion. The ComHIP implementation has the following 
components: (1) Community- based education on CVD 
risk factors and healthy lifestyles; (2) Community- based 
screening and monitoring of blood pressure by LCS 
and CVD nurses; (3) Community- based diagnosis, treat-
ment, counselling, follow- up and referral of hypertension 
patients (when needed) by CVD nurses; (4) Telemedicine 
consultation by CVD nurses and referral of patients with 
severe hypertension and/or organ damage to a physician; 
(5) ICT messages for healthy lifestyles, treatment adher-
ence support and treatment refill reminders for hyper-
tension patients and (6) Commcare, a cloud- based health 
records system linked to short- message service (SMS)/
voice messaging for treatment adherence, reminders and 
health messaging.14 ComHIP was implemented in the 
district of Lower Manya Krobo (from now on, the inter-
vention district). A total of 1339 individuals were enrolled 
in the programme by December 2016.15 A full list of 
ComHIP activities can be found in online supplemental 
tables S1 and S2 in the supporting information file. For 
more details about the ComHIP implementation see 
Adler et al.15 ComHIP was independently evaluated by the 
Ghana School of Public Health and the London School 
of Hygiene and Tropical Medicine—the evaluation 
included several substudies. The main study was a cohort 
study of hypertensive individuals enrolled in ComHIP in 
the intervention district.15 The primary outcome of this 
cohort study was hypertension control, and secondary 
outcomes included changes in blood pressure and knowl-
edge of risk factors for hypertension.15 The authors found 
that after 12 months of intervention, 72% of patients had 
their hypertension controlled and that systolic/diastolic 
blood pressure were reduced, respectively, by 12.2 and 
7.5 mm Hg.15 In addition to the cohort study, the study 
team performed two repeat cross- sectional surveys at 
baseline and endline, one in the intervention district and 
one in a control district.14 The primary outcomes of the 
surveys included hypertension prevalence, hypertension 
awareness, proportion of individuals under treatment, 
hypertension control and blood pressure levels.14 Finally, 
the evaluation included a cost- effectiveness analysis, the 
results of which we report here.
Cost-effectiveness analysis design
We performed a cost- effectiveness modelling exercise, 
estimating the incremental costs per disability- adjusted 
life- year (DALY) averted, of ComHIP compared with 
standard hypertension care (ie, current hypertension 
management practice by the GHS) for a general popu-
lation of adult individuals aged 18–79 in Ghana. This 
choice of population was made to be able to represent all 
individuals in the community.
We modelled two scenarios for ComHIP. The first 
scenario, current ComHIP scale- up, was characterised by 
the existing implementation of ComHIP in a hypothet-
ical scale- up to a general population of 10 000 adult 
individuals. In this population, the prevalence of hyper-
tension was estimated based on the total proportion of 
hypertensive patients found across the intervention and 
control districts by the cross- sectional survey undertaken 
by the research team at endline (=33.68%). The scenario 
involved the annual provision of ComHIP- related services 
by the GHS and LCS with support from FHI360. The 
second scenario, GHS- LCS ComHIP scale- up, was character-
ised by the implementation of ComHIP by the GHS and 
LCS without assuming continuing support from FHI360 in 
the same population. The difference between the current 
ComHIP scale- up and the GHS- LCS ComHIP scale- up 
scenario is that the former scenario uses FHI360 unit costs 
while the latter uses local unit costs for cost estimation. We 
took this approach as some of the unit costs incurred by 
FHI360 are higher than local unit costs. These scenarios 
were compared with standard care, which was character-
ised by the existing hypertension management by the 
GHS in a hypothetical scale- up to a general population 
of 10 000 adult individuals. Online supplemental table 
S3 in the supporting information file provides further 
details about the resource consumption characterising 
the programme costs estimated for the scale- up of the two 
ComHIP scenarios and of the standard hypertension care 
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scenario. We note here that although developing a hypo-
thetical scenario with a ComHIP scale- up to the entire 
population of the country or to the entire population of a 
region would have been preferable, estimating with some 
degree of accuracy the resource consumption character-
ising the programme costs which is required for such a 
scale- up was not deemed possible.
The cost- effectiveness analysis was conducted over 
a time frame of 10 years from a societal perspective 
including healthcare provider and patient costs. Our 
analysis included extensive primary data collection of the 
costs of hypertension management from both a provider 
and patient perspective, combined with effectiveness data 
from the ComHIP patient cohort and a decision analytical 
model to estimate costs and health impact over the time 
frame of the study. The estimation of all input parameters 
is described below.
The decision analytical model
In order to estimate the cost- effectiveness of ComHIP 
compared with standard hypertension care, we developed 
a Markov model that estimated costs and health outcomes 
associated with the two interventions over a time period 
of 10 years. The main hypothesis of the model was that 
better hypertension control under ComHIP reduces the 
risk of CVD events compared with standard hypertension 
care. These CVD events can be coronary heart disease 
(CHD) (including angina and myocardial infarction) 
and stroke. Lower risk of CVD events leads to a reduction 
in the number of DALYs lost to patients over the period 
covered by the model. The Markov model is further 
described in section 1.1.2 and online supplemental figure 
S1 of the supporting information file. The model was 
implemented using Treeage Pro software.16
Probabilities of stroke and CHD events
We used the Framingham 10- year risk equations for 
stroke and CHD (myocardial infarction and angina)17 18 
to estimate the probabilities of stroke and CHD events 
for the ComHIP and standard care scenarios as a func-
tion of individual patient characteristics such as blood 
pressure levels, age, gender, smoking status and clinical 
history. Initially, we aimed to obtain this information from 
individuals on hypertension treatment in the surveys 
undertaken in the intervention (ComHIP) and control 
(standard care) districts at the end of the ComHIP evalu-
ation. However, the number of individuals who reported 
being on treatment for hypertension in these surveys was 
very low (33 in total across both districts). To obtain the 
data to populate the Framingham equations, we used 
individual- level information available from the cohort 
study, an observational study of patients on ComHIP 
without a control group of patients on standard hyperten-
sion care. Demographic, behavioural and clinical history 
information in these patients was available at enrolment 
into the study. At enrolment, patients also reported 
whether they were on hypertension treatment. Data on 
blood pressure levels was available at enrolment into the 
study and over time as patients went for clinical consul-
tations or blood pressure control visits. To estimate the 
probabilities of stroke and CVD events in the ComHIP 
and standard care scenarios, we applied the Framingham 
10- year risk equations for stroke and CHD to individual 
patient characteristics (average systolic and diastolic 
blood pressure, age, gender, self- reported smoking status, 
self- reported diabetes status, estimated total- to- high- 
density- lipoprotein (HDL) cholesterol level) comparing 
two groups of patients:
 ► For ComHIP, we used the characteristics from all 
patients who were on antihypertensive medication 
in the programme for at least 12 months (n=219). 
The effect of ComHIP on blood pressure was oper-
ationalised in these patients by using the latest blood 
pressure readings available from these patients as 
close as possible to the date of their last medication 
prescription.
 ► For standard care, we used the characteristics from 
the subgroup of the 219 patients described above who 
had reported being on the standard hypertension 
care at recruitment into the study (n=142). The effect 
of standard care on blood pressure was operation-
alised in these patients by using the blood pressure 
readings available from these patients at enrolment 
into the study.
For ComHIP, the choice of the 219 patients who were on 
hypertensive medication for at least 12 months was moti-
vated by the risk of bias associated with including patients 
lost to follow- up. These patients may have experienced 
a temporary drop in blood pressure while on ComHIP, 
but we could not assume that this drop would be main-
tained after loss to follow- up or impact their longer- term 
blood pressure levels or CVD risk. For standard care, the 
inclusion of the subgroup of these 219 patients who had 
reported being on hypertension treatment at study enrol-
ment was motivated by the evaluation study design. While 
there were no longitudinal patient- level data available 
(including data on blood pressure over time or on losses 
to follow- up) from an equivalent cohort of patients on 
standard care, there were both data on the standard care 
treatment status and blood pressure levels when these 
patients were enrolled in the study.
The two groups of patients were comparable in that 
they did not differ substantially in terms of blood pres-
sure, key demographic or behavioural characteristics at 
enrolment into the ComHIP study. Furthermore, they did 
not differ substantially in terms of blood pressure levels 
at the time of the last blood pressure measurement (see 
online supplemental table S4 in the supporting informa-
tion file).
Using the Framingham risk equations, we estimated 
the n- year probabilities of CHD and stroke events (n=1–
10) in both sets of individual patient data. We then used 
standard formulas to convert these n- year probabilities 
to 1 year probabilities (ie, the probability of an event 
between year n and year n+1). We allowed for repeat 
stroke/CHD events under the assumption, for simplicity, 
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that the probability of a repeat event was not changed by 
a previous event. We used beta probability distributions19 
to express uncertainty in the annual probabilities—
summary measures of these probabilities can be found in 
online supplemental tables S5 and S6 in the supporting 
information file.
The annual probabilities of treatment for first/repeat 
stroke/CHD and the annual probabilities of death after 
treatment for first/repeat stroke/CHD were obtained 
from an expert opinion exercise with two experienced 
clinicians from the GHS, as there are no data available for 
these probabilities in the peer- reviewed literature. Each 
of the two clinicians was asked to provide a low/average/
high estimate for these probabilities based on his/her 
clinical experience. We averaged the results of the expert 
opinion elicitation exercise across the two clinicians. We 
used triangular probability distributions to express uncer-
tainty in these annual probabilities. Summary measures 
of these probabilities are available in online supplemental 
table S7 in the supporting information file.
The probabilities of hypertension patients dying from 
causes other than CVD and of no hypertension patients 
dying from any cause were estimated from the Global 
Burden of Disease study20—see section 1.2.1 in the online 
supplemental file for more details.
Costs
Our model includes six cost- incurring health states (no 
hypertension, hypertension, treated first CHD event, 
treated repeat CHD event, treated first stroke event, 
treated repeat stroke event). We estimated the annual 
societal cost per individual (no hypertension) and per 
patient (hypertension, treated first CHD event, treated 
repeat CHD event, treated first stroke event, treated 
repeat stroke event) for each of the two ComHIP scenarios 
and for the standard care scenario for the 10- year period 
of the analysis. For all patient costs, annual societal costs 
were separated into annual costs accruing to the health-
care provider and annual costs accruing to the patient 
(ie, patient- level costs). Healthcare provider costs were 
separated into the costs of health service provision to 
patients (variable costs) and into overhead costs. For all 
health states, we estimated separately the costs of the first 
year and the costs of subsequent years.
For the healthcare provider costs of no hypertension, 
we estimated the hypertension screening costs per indi-
vidual from the ComHIP database and assigned it to the 
portion of the population in the intervention/control 
districts which were not hypertensive. For the health-
care provider costs of hypertension, our starting point 
for estimating the annual costs per patient of current 
ComHIP scale- up was the estimation of the annual costs 
of healthcare provision to patients, including screening 
(ie, the time of healthcare staff, the medication and diag-
nostic tests consumed per patient per year) from data in 
the ComHIP cohort database. For the cost- effectiveness 
model, these costs were estimated in the sample of 219 
patients who were on treatment for at least 12 months in 
ComHIP, as this was the sample of patients used for the 
calculation of intervention effectiveness. For the estima-
tion of the annual costs of implementing the ComHIP 
programme, we adjusted these costs by the losses to 
follow- up during the first year on ComHIP. Once we esti-
mated the annual costs of health service provision we esti-
mated the annual overhead costs, that is, the costs of the 
resources not directly related to health service provision. 
For this task, we undertook an ingredients- based costing 
exercise of ComHIP activities. Following standard costing 
methodology,21 these activities were divided into those 
corresponding to the start- up period (the period during 
which the project was set up, that is, before the imple-
mentation of any patient- related activities) and into the 
postimplementation period (further details can be found 
in section 1.1.1. and online supplemental table S1 and S2 
in the supporting information file). We adjusted all quan-
tities by the changes in programme activities assumed for 
the scale- up of the project to serve a general population 
of 10 000 individuals (see online supplemental table S3 in 
the supporting information file). For GHS- LCS ComHIP 
scale- up we used the same approach and data but valuing 
all services currently provided by FHI360 at local prices. 
Further details of these cost calculations can be found in 
section 1.1.3 of the supporting information file.
The estimation of the annual healthcare provider costs 
of hypertension per patient in standard care was based 
on an expert opinion elicitation exercise with three 
clinical experts. We used this approach as we could not 
find information on detailed resource consumption for 
hypertension patients over a follow- up period of 1 year 
in the Ghanaian literature. Overhead costs for standard 
care (technical staff support, administrative staff support, 
medical and office equipment, vehicles) were estimated 
based on the overhead costs of ComHIP but excluding the 
cost of ComHIP- specific activities (training, programme 
coordination, app development and support) as shown 
in online supplemental table S3 in the supporting infor-
mation file.
Annual individual and patient- related costs of hyper-
tension screening and management in ComHIP were esti-
mated using a survey of ComHIP patients (n=257) and 
in standard care using a survey of patients with hyperten-
sion in the district not in ComHIP (n=130). Patients were 
asked questions about the direct medical expenditures, 
direct non- medical expenditures and productivity losses 
due to time seeking treatment and time lost to work (both 
valued at the reported monthly income)—see online 
supplemental table S8 in supporting information file.
A breakdown of the annual societal costs per patient 
for standard care, including both healthcare costs and 
patient- related costs can be found in online supplemental 
tables S9–S11 in the supporting information file.
Annual CHD and stroke healthcare provider costs were 
estimated using clinical expert opinion elicitation exer-
cises and annual CHD and stroke patient costs using a 
mix of clinical expert opinion and data from the same 
patient surveys as above—for more details see online 
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supplemental tables S12–S14. Annual societal costs 
for CVD treatment in the ComHIP and standard care 
scenarios are shown in online supplemental table S15.
We used gamma probability distributions19 to express 
uncertainty in the costs per patient of the hypertension 
health state for ComHIP and triangular probability distri-
butions over a wide range (±30%) to express uncertainty 
in the annual costs of no hypertension, of hypertension 
for standard care and in the annual costs of CVD- related 
health states.
Disability weights
Disability weights for the different health states included 
in the Markov model (hypertension, CHD/treated, 
CHD/untreated, stroke/treated, stroke/untreated) were 
drawn from the Global Burden of Disease 2016 study.20 
The uncertainty range for these parameters was based 
on varying degrees of severity for each condition also 
from the same study (see online supplemental table S16 
in the supporting information file). The death state was 
assigned a disability weight of 1. We used triangular prob-
ability distributions to express uncertainty in the disability 
weights.
Analysis
We estimated the mean incremental cost per DALY averted 
of the ComHIP scenarios compared with standard care. 
All results are expressed in constant 2017 US$ using the 
average 12- month exchange rate between the US$ and 
the Ghanaian cedi for 2017 (US$1=GH₵4.38).22 Costs 
and health outcomes were discounted at an annual rate 
of 3%. We used the most recent estimate of the willing-
ness to pay (WTP) threshold reflecting opportunity costs 
from Ghana23 adjusted for inflation (=US$645) and, in 
sensitivity analysis, the Ghanaian gross domestic product 
(GDP) per capita for 2017 (=2025 US$).24 The GDP per 
capita has been used as a cost- effectiveness threshold in 
published evaluations of similar interventions—see, for 
example, Roseendal et al10 and Gaziano et al.25 Uncer-
tainty in the input parameters was assessed using a proba-
bilistic sensitivity analysis (PSA; Monte Carlo simulation) 
in which input parameters were randomly sampled from 
their respective distributions in 10 000 iterations. We 
performed a sensitivity analysis on the estimation of CVD 
probabilities using the WHO CVD Risk Chart Working 
Group CVD risk charts for Western SSA.26 For details, 
see section 2.1.2 and online supplemental tables S17 and 
S18 in the supporting information file. In addition, we 
performed a threshold analysis on key parameters (shown 
in section 2.1.3 and online supplemental table S19 in the 
supporting information file).
In addition to the above, as our comparison focuses 
only on those retained on care, we performed a scenario 
analysis modelling the cost- effectiveness of ComHIP and 
standard care including in both interventions lost to 
follow- up in hypertension treatment during the first year:
 ► For ComHIP, out of 905 individuals aged 18–79 in the 
ComHIP cohort who started treatment, 686 (76%) 
were lost to follow- up before the end of the first year. 
To incorporate first- year losses to ComHIP follow- up 
into the Markov model, we estimated the annual risk 
of CHD/ stroke of these 686 individuals using their 
last available blood pressure readings. We estimated 
the first- year hypertension treatment costs of these 
individuals for their duration of follow- up.
 ► For standard care, we had no data on lost to follow- up, 
so we used the proportions of those receiving standard 
care at enrolment to those who were not receiving 
standard care at enrolment (56%:44%) as an indi-
rect estimate of first- year lost to follow- up. We then 
estimated separately the annual risk of CHD/ stroke 
for individuals in the two groups using their blood 
pressure readings at the time of enrolment into the 
ComHIP cohort. We also adjusted the first- year costs 
for those estimated to be lost to follow- up assuming 
that they spent on average the same amount of time 
on treatment as those lost to follow- up in the ComHIP 
cohort. Finally, we also explored a second scenario 
where standard care had as high a lost to follow- up as 
ComHIP (76%).
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
RESULTS
Costs of hypertension across scenarios
Table 1 shows the annual societal costs of hyperten-
sion management in the base case for the two ComHIP 
scenarios and for the standard care scenario. These are 
the total annual costs (including hypertension screening, 
diagnosis and treatment) to the healthcare provider 
and to patients of implementing ComHIP and standard 
care for a population of 10 000 adults in the intervention 
district. A detailed breakdown of these costs is provided 
in section 2.2 and online supplemental tables S20–S22 of 
the supporting information file.
From table 1, current ComHIP scale- up is estimated to 
have an annual societal cost of US$903 285—it is 20% more 
costly than GHS- LCS ComHIP scale- up at US$751 322 
per year—this difference is due to the lowering of unit 
costs (for the most part salaries) in the transfer of services 
between FHI360 and the GHS. At US$462 636 per year, 
standard care annual societal costs are 51% and 62% 
of the costs of current ComHIP scale- up and GHS- LCS 
ComHIP scale- up, respectively. With respect to the costing 
structure, note that postimplementation costs make 
up the bulk of all annual costs (96% and 98% for each 
respective ComHIP scenario and 100% for the standard 
care scenario). Of these postimplementation costs, the 
largest cost driver is health service provision (the time of 
healthcare staff, the medication and diagnostic test costs, 
the patient- level costs including time seeking health-
care, out- of- pocket expenditures and time lost to work, 
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Table 1 Annual societal costs of hypertension screening, diagnosis and treatment (2017 US$)
Scenario Healthcare provider costs Patient- level costs Societal costs %
SCENARIO (no of patients on hypertension treatment) CURRENT ComHIP SCALE- UP (n=3368)







  1. ComHIP app development 5229 - 5229 16
  2. Training 11 338 - 11 338 34
  3. Management 16 529 - 16 529 50









  1. ComHIP app support 15 672 - 15 672 2
  2. Acquisition of clinical and IT equipment 20 849 - 20 849 2
  3. Health service provision to hypertensive patients 179 845 385 633 565 478 65
  4. Health service provision to non- hypertensive individuals 42 820 8910 51 730 6










  Overhead costs=total annual costs − health service provision 286 076
  Overhead costs per patient 84.94
SCENARIO (no of patients on treatment) GHS- LCS ComHIP SCALE- UP (n=3368)







  1. ComHIP app development 207 - 207 1
  2. Training 8955 - 8955 58
  3. Management 6338 - 6338 41









  1. ComHIP app support 7660 - 7660 1
  2. Acquisition of clinical and IT equipment 20 849 - 20 849 3
  3. Health service provision to hypertensive patients 179 845 385 633 565 478 77
  4. Health service provision to non- hypertensives 42 820 8910 51 730 7










  Overhead costs=total annual costs - Health service provision 134 115
  Overhead costs per patient 39.82
  SCENARIO (no of patients on treament) STANDARD CARE (n=3368)
Annual start- up costs - - - 0
  1. ComHIP app development - - - -
  2. Training - - - -
  3. Management - - - -
Annual post- implementation costs 253 356 209 280 462 636 100
  1. ComHIP app support - - - 0
  2. Acquisition of clinical and IT equipment 9929 - 9929 2
  3. Health service provision to hypertensive patients 192 527 209 280 401 807 87
  4. Management 50 900 - 50 900 11
Total annual costs 253 356 209 280 462 636 100
  Overhead costs=total annual costs − health service provision 60 829
  Overhead costs per patient 18.06
Sources: own calculation based on cost analysis.
*Incremental costs with respect to the annual costs of the standard care scenario.
ComHIP, Community- based Hypertension Improvement Project; GHS- LCS, Ghana Health Service- licensed chemical seller.
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and the costs of screening non- hypertensives) with 71%, 
84% and 87% of the postimplementation costs respec-
tively, followed by the programme management costs 
(coordination meetings and field activities, technical staff 
support, administration costs) with 25%, 12% and 11%, 
respectively. Importantly, note the cost structure from 
table 1 results in an annual overhead cost per patient that 
differs substantially across scenarios—US$84.94 for the 
current ComHIP scale- up scenario, about twice as large 
as for the GHS- LCS ComHIP scale- up scenario and four 
times as large as for standard care. For the estimation of 
the annual programme costs, with lost to follow- up, the 
average annual societal costs per patient were US$197.20 
in current ComHIP scale- up, US$152.10 in GHS- LCS 
ComHIP scale- up and US$119.63 in standard care.
For the cost- effectiveness analysis, with no losses to 
follow- up, the average societal costs per patient in year 
1 with initial diagnosis (without initial diagnosis) were 
US$264.17 (US$244.56) in current ComHIP scale- up, 
US$219.05 (US$199.44) in GHS- LCS ComHIP scale- up, 
and US$157 (US$141) in standard care. Of note, current 
ComHIP care was on average 68% (73%) more expensive 
per patient than standard hypertension care. GHS- LCS 
ComHIP scale- up was on average between 39% (41%) 
more expensive per patient than standard care. The 
main cost drivers for these cost differences were, first, 
the differences in overhead costs and, second, the differ-
ence in patient- level costs which is mainly due to a higher 
number of visits to the healthcare provider in ComHIP.
Cost-effectiveness analysis
Table 2 presents the total costs in the base case of the 
different scenarios over 10 years separated into cost 
components.
From table 2, note that the overhead costs of hyperten-
sion and the patient- level costs are the main cost drivers of 
the differences in 10- year costs between scenarios. Partic-
ularly, note how the overhead costs of current ComHIP 
scale- up are more than four times the overhead costs 
of standard care and the patient- level costs of current 
ComHIP scale- up are 80% greater than the patient- level 
costs of standard care.
Table 3 shows the results of the base- case cost- 
effectiveness analysis.
From table 3, in the base case, ComHIP helps 
prevent on average 75 CHD events and 45 strokes in a 
Table 2 10- year costs of different scenarios by cost component (2017 US$)
Current ComHIP 
scale- up %




Total costs (Incremental costs*)
Health service costs 1 386 292
(−199 408)
18 1 386 292
(−199 408)
22 1 585 700 32
Overhead costs 2 215 779
(1 752 299)
30 1 038 827
(575 347)
16 463 480 9
Patient- level costs 2 863 469
(1 268 919)
39 2 863 469
(1 268 919)
46 1 594 550 33




16 1 260 760 26




100 6 262 778
(1 358 288)
100 4 904 490 100
Sources: own calculation based on cost- effectiveness modelling.
*Incremental costs with respect to the costs of the standard care scenario.
ComHIP, Community- based Hypertension Improvement Project; CVD, cardiovascular disease; GHS- LCS, Ghana Health Service- licensed 
chemical seller.










Standard care 4 904 490 238/285 7883
Current ComHIP scale- 
up
7 439 730 2 535 240 193/210 45/75 7675 208 12 189
Standard care 4 904 490 238/285 7883
GHS- LCS ComHIP 
scale- up
6 262 778 1 358 288 193/210 45/75 7675 208 6530
CHD, coronary heart disease; ComHIP, Community- based Hypertension Improvement Project; CVD, cardiovascular disease; DALY, disability- 
adjusted life- year; GHS, Ghana Health Service; ICER, incremental cost- effectiveness ratio; LCS, licensed chemical seller.
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general population of 10 000 individuals over a period 
of 10 years. Cases averted are driven in the model by 
the lower average blood pressure levels estimated for 
ComHIP (systolic=132.27 mm Hg; diastolic=81.04 mm 
Hg) compared with standard care (systolic=147.65; 
diastolic=90.14). 208 DALYs are averted overall. The 
incremental cost- effectiveness ratio (ICER) of current 
ComHIP scale- up versus standard care is US$12 189 per 
DALY averted. For a WTP threshold of US$645 per DALY 
averted23 current ComHIP scale- up is not cost- effective, 
and neither is it for a WTP threshold of 1 GDP per capita 
(=2025 US$).24 The ICER of GHS- LCS ComHIP scale- up 
is US$6530 per DALY averted, also not cost- effective for 
the same WTP thresholds.
Figure 1 shows, for the base case, the cost- effectiveness 
acceptability curves resulting for both comparisons from 
the probabilistic sensitivity analysis (PSA) reflecting 
uncertainty in the model inputs (the incremental cost- 
effectiveness scatterplots are shown in online supple-
mental figures S2 and S3 in the supporting information 
file).
From figure 1, considering uncertainty in the input 
parameters, the probability that current ComHIP scale- up 
is cost- effective is 0% at WTP= US$ 645 and 0.45% at 
WTP= US$2025. The probability that GHS- LCS ComHIP 
scale- up is cost- effective is 0.8% at WTP= US$645 and 
11.5% at WTP= US$2025.
Table 4 shows the incremental cost- effectiveness of both 
ComHIP scenarios compared with standard hyperten-
sion care after incorporating drop- outs in hypertension 
treatment.
Assuming a drop- out rate of 44% in standard care, 
current ComHIP scale- up has an estimated ICER of 
US$7363 per DALY averted and is not cost- effective at 
any of the two WTP thresholds. In contrast, GHS- LCS 
ComHIP scale- up is both more effective and less costly 
than standard care, which is now the dominated alter-
native. This is because fewer drop- outs in standard care 
result in higher overall treatment costs than in GHS- LCS 
Figure 1 Cost- effectiveness acceptability curves in the 
base case: Current ComHIP scale- up and GHS- LCS ComHIP 
scale- up versus standard care. ComHIP, Community- based 
Hypertension Improvement Project; GHS, Ghana Health 
Service; LCS, licensed chemical seller; WTP, willingness to 
pay.
Table 4 Cost- effectiveness analysis (including drop- outs)
Intervention Cost (US$) Incremental cost (US$) DALYs DALYs averted ICER
Current ComHIP scale- up (76% drop- outs year 1) vs standard care (44% drop- outs year 1)
Standard care 3 583 740 7811
Current ComHIP scale- up 4 482 100 898 360 7689 122 7363
GHS- LCS ComHIP scale- up (76% drop- outs year 1) vs standard care (44% drop- outs year 1)
Standard care 3 583 740 7811 Dominated
GHS- LCS ComHIP scale- up 3 371 850 (211 890) 7689 122
Current ComHIP scale- up (76% drop- outs year 1) vs standard care (76% drop- outs year 1)
Standard care 2 630 690 7817
Current ComHIP scale- up 4 482 100 1 851 410 7689 128 14 462
GHS- LCS ComHIP scale- up (76% drop- outs year 1) vs standard care (76% drop- outs year 1)
Standard care 2 630 690 7817
GHS- LCS ComHIP scale- up 3 371 850 741 160 7689 128 5789
ComHIP, Community- based Hypertension Improvement Project; DALY, disability- adjusted life- year; GHS, Ghana Health Service; ICER, 
incremental cost- effectiveness ratio; LCS, licensed chemical seller.
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ComHIP scale- up which are not compensated by a higher 
impact on health outcomes—we did not pick up a higher 
hypertension control in those reporting being on treat-
ment with standard care vs those reporting not being on 
treatment. Assuming a drop- out rate of 76% in standard 
care, neither current ComHIP scale- up nor GHS- LCS 
ComHIP scale- up are cost- effective at the same thresholds 
with respective ICERs being US$14 462 per DALY averted 
and US$5789 per DALY averted.
DISCUSSION
Our study found that ComHIP is unlikely to be a cost- 
effective health intervention in Ghana for two different 
cost- effectiveness thresholds: one (lower) opportunity- 
cost- based threshold23 and one (higher) based on the 
Ghanaian GDP per capita. Our base case results were 
robust considering the uncertainty associated with our 
underlying assumptions (including substantial uncertainty 
in the costs of CHD and stroke treatment and uncertainty 
associated with the annual probability of CHD and stroke 
events). However, our economic evaluation is fundamen-
tally limited by the evidence quality associated with the 
effectiveness estimates, which come from observational 
data rather than from a randomised control study design. 
Nevertheless, our study provides some important findings. 
First, this is one of the first studies examining the cost- 
effectiveness of hypertension screening and treatment 
using a community scale- up model. This model incorpo-
rates community- based education on CVD risk factors and 
healthy lifestyles, screening and hypertension monitoring 
by community pharmacists and CVD nurses, community- 
based hypertension diagnosis, treatment, counselling and 
follow- up with a cloud- based app for health record system 
linked to SMS/voice messaging for treatment adherence 
support and health messaging.14 We find much higher 
overhead costs (related to the cost of development of the 
app, mobile devices, training of community pharmacists 
and clinical staff, coordination meetings and field activ-
ities) and patient- level costs in both ComHIP scenarios. 
This substantial increase in costs, even when accounting 
for the higher prices used in international support asso-
ciated with the current ComHIP scale- up suggests that 
the costs of ensuring appropriate care are high; and in 
this case could not produce sufficient impact to achieve 
cost- effective implementation. Second, our study adopts 
a societal perspective and thus incorporates not only the 
costs to the GHS but also the costs to patients of being on 
hypertension treatment (which are not inconsiderable in 
the Ghanaian context) and also estimates of the costs of 
informal care of patients suffering from CVD events.
Our results add to the growing body of evidence on 
the cost- effectiveness of providing hypertension care in 
LMICs. In Vietnam, Nguyen et al27 estimated the cost- 
effectiveness of alternative hypertension screening 
options (namely, varying intervals for screening and 
varying ages to start screening) compared with no hyper-
tension screening using a Markov model over 10 years 
in the base case. They used the Asia Cardiovascular Risk 
Prediction Model to estimate the probabilities of CVD 
events and, like us, modelled repeat CVD events, using a 
provider perspective. It is unclear whether they included 
the health system costs of supporting service delivery 
or just the prices of commodities. They found that for 
most scenarios the intervention was cost- effective. In 
Nigeria, Rosendaal et al10 evaluated the cost- effectiveness 
of population- level screening and subsequent treatment 
compared with no screening or treatment. They used a 
Markov model over 10 years and did not model repeat 
CVD events. They used different assumptions to model 
CVD events, including (like us) the Framingham risk 
equations. For the costs, which were based on an existing 
costing study28 and on clinical guidelines, they used the 
healthcare provider perspective. Using a WTP threshold 
of 1× GDP per capita (US$2742), they found that hyper-
tension screening, with incremental costs per DALY 
averted ranging from US$732 to US$7815, could be cost- 
effective under most assumptions. When using the Fram-
ingham risk equation, they found hypertension screening 
was either not cost- effective or borderline cost- effective 
depending on the patient eligibility criteria. Finally, there 
is a third study by Gaziano et al25 conducted in Guatemala, 
Mexico and South Africa. They evaluated the potential 
cost- effectiveness (from a healthcare provider perspec-
tive, ie, excluding patient- level costs) of using commu-
nity health workers to screen for CVD in community 
settings using a paper- based tool or a mobile app and a 
Markov model over the lifetime of individuals. The study 
used CVD risk equations developed by the authors and 
modelled repeat CVD events. They found that the inter-
vention was either cost- saving or highly cost- effective in 
all settings. In summary, the results from the literature 
are not conclusive. Among the possible explanations for 
the difference between our results and those of the other 
studies are the following:
1. The use of different risk prediction models.
2. The use of different periods for the estimation of ef-
fectiveness—in particular, Nguyen et al27 and Gaziano 
et al25 estimated effectiveness over the lifetime of indi-
viduals. Hypertension patients in younger age groups 
have a lower 10- year risk but a higher lifetime risk of 
CVD, especially those of African descent.10 29 30 This 
may have led to an underestimate of health outcomes 
in our study which estimated health outcomes over a 
period of 10 years.
3. The range of costs included—for example, none of 
the studies except ours used the societal perspective—
hence, they did not include any patient- related costs in 
the analysis. In addition, it is not clear if Nguyen et al27 
included the health system costs of supporting health 
service delivery; similarly, it is not entirely clear the 
extent to which Gaziano et al25 included the overhead 
costs of administration and other supportive services 
into their cost estimates.
4. The use of different decision rules for establishing 
cost- effectiveness. For example, Nguyen et al27 used 
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as a much higher threshold for cost- effectiveness (3 × 
GDP per capita=US$15 000) than we did. It is unclear if 
their results would hold at the opportunity- cost based 
threshold of current US$1602.23
Our results add to the evidence that current models of 
hypertension screening are unlikely to be cost- effective; 
and that much more work is still required to develop 
methods of implementation to address this growing 
burden of disease related to hypertension in LMICs.
The Markov model that we have implemented in this 
cost- effectiveness study has several limitations. While we 
tried to test sensitivity to loss to follow- up, our evidence 
base is weak. In a recent study using data from the 
Ghana DHS about 60% of patients with hypertension 
are estimated not to follow treatment.9 Clearly, differ-
ences in the patients dropping out between ComHIP 
and standard care would affect cost- effectiveness, should 
ComHIP retain more people in care. In fact, retention 
levels were low, including a 3- month period where due 
to operational levels there was a gap in the provision 
of Commcare services.15 We did not explore the effects 
on blood pressure and costs of the interventions in the 
short term (ie, under 1 year). This was due to the lack of 
follow- up data from patients on standard care. In addi-
tion, the estimation of CVD patient- level costs included 
data from few individuals (n=7). Although these data 
were supplemented with expert opinion from clinicians 
and the resulting costs estimates were subjected to sensi-
tivity analysis, we acknowledge its limitations. Further, 
the model relies on the Framingham risk equations to 
estimate the risk of CVD events. These equations were 
estimated based on a cohort of hypertensive patients 
from the USA, and hence are not validated for patients 
from Ghana. We chose to model cost- effectiveness over 
a period of 10 years (the time span for which the Fram-
ingham equations provide predicted CVD probabilities) 
and did not project cost- effectiveness over the lifetime of 
the cohort. As mentioned before, hypertension patients 
in younger age groups have a lower 10- year risk but a 
higher lifetime risk of CVD, which means that we may have 
underestimated the health outcomes and hence the cost- 
effectiveness of ComHIP by not extending the modelling 
to the lifetime of the cohort. In addition, the Framingham 
equations were used to estimate the effect of short- term 
changes in blood pressure on the risk of stroke and CHD 
for patients under treatment for these conditions. This 
may have led to an overestimation of the annual proba-
bilities of stroke and CHD in the cost- effectiveness model. 
Furthermore, as in other cost- effectiveness studies of 
hypertension interventions, we only modelled CHD and 
stroke as possible adverse events of hypertension. This is 
due to lack of data about the relationship between hyper-
tension and the risk of other illnesses, but it likely led to 
an underestimate of the benefits of ComHIP. In addition, 
for pragmatic reasons, we used triangular distributions to 
characterise uncertainty in the following parameters—
the probability of treatment for first time/repeat stroke 
or CHD, the probability of death after first time/repeat 
stroke or CHD, the cost of hypertension treatment in the 
standard care scenario and the cost of screening non- 
hypertensives. An improved characterisation of uncer-
tainty would have involved modelling this uncertainty in 
these parameters with gamma or beta distributions.
CONCLUSION
Hypertension is a growing global public health issue, for 
which effective treatment is available. While our study 
does not demonstrate positive economic evidence on 
the ComHIP model of care, it is critical to note that our 
result was driven by the way the intervention was deliv-
ered. Unfortunately, ComHIP failed to develop a model 
of delivery that achieved sufficient levels of retention and 
use at an acceptable cost. Our study along with others, 
suggests that there is an urgent remaining need for a 
substantial programme of global research, using sound 
study designs, to establish cost- effective ways of delivering 
this effective treatment to the populations who need it in 
LMICs.
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